Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tamoxifen. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 8/20 | 0.97 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.97 |
| ▸ | MAPT | P10636 | 3/20 | 0.97 |
| ▸ | MEN1 | O00255 | 3/20 | 0.97 |
| ▸ | TP53 | P04637 | 3/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.97 |
| ▸ | ESRRG | P62508 | 3/20 | 0.97 |
| ▸ | PGR | P06401 | 2/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.97 |
| ▸ | HTR6 | P50406 | 2/20 | 0.97 |
| ▸ | NPC1 | O15118 | 1/20 | 0.97 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.97 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.97 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.97 |
| ▸ | EGFR | P00533 | 1/20 | 0.97 |
| ▸ | GBA1 | P04062 | 1/20 | 0.97 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.97 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29659348 | 0.99 | ESR1 (1.00) | ESR1ESR2MAPTMEN1TP53 | |
| Tamoxifen SCHEMBL17262111 | 0.99 | ESR1 (1.00) | ESR1ESR2MAPTMEN1TP53 | |
| Tamoxifen SCHEMBL4084 | 0.99 | ESR1 (1.00) | ESR1ESR2MAPTMEN1TP53 | |
| Tamoxifen SCHEMBL17262082 | 0.99 | ESR1 (1.00) | ESR1ESR2MAPTMEN1TP53 | |
| Tamoxifen SCHEMBL4085 | 0.99 | ESR1 (1.00) | ESR1ESR2MAPTMEN1TP53 | |
| Tamoxifen SCHEMBL1056785 | 0.99 | ESR1 (1.00) | ESR1ESR2MAPTMEN1TP53 | |
| Tamoxifen SCHEMBL119181 | 0.99 | ESR1 (1.00) | ESR1ESR2MAPTMEN1TP53 | |
| Tamoxifen SCHEMBL3794383 | 0.97 | ESR1 (0.97) | ESR1ESR2MAPTMEN1TP53 | |
| Tamoxifen SCHEMBL17629799 | 0.97 | ESR1 (0.97) | ESR1ESR2MAPTMEN1TP53 | |
| Tamoxifen SCHEMBL4323842 | 0.97 | ESR1 (0.97) | ESR1ESR2MAPTMEN1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110167564-A | Modulation of tjp1 expression to regulate regeneration of cardiac cells | 新加坡科技研究局 | 2019-08-23 | — | — | CN | disclosed |
| CN-108938613-A | The purposes of tamoxifen and a kind of method for constructing cleft palate animal model | 首都医科大学附属北京口腔医院 | 2018-12-07 | — | — | CN | disclosed |
| US-8377886-B2 | Use of gamma secretase inhibitors and notch pathway inhibitors for treatment and prevention of renal disease | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2013-02-19 | — | — | US | disclosed |
| US-20100222283-A1 | USE OF GAMMA SECRETASE INHIBITORS AND NOTCH PATHWAY INHIBITORS FOR TREATMENT AND PREVENTION OF RENAL DESEASE | ALBERT EINSTEIN COLLEGE OF MEDICINE | 2010-09-02 | — | — | US | disclosed |
| WO-2009035522-A1 | USE OF GAMMA SECRETASE INHIBITORS AND NOTCH PATHWAY INHIBITORS FOR TREATMENT AND PREVENTION OF RENAL DISEASE | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2009-03-19 | — | — | WO | disclosed |
| US-20080318839-A1 | Ligand activated transcriptional regulator proteins | THE SCRIPPS RESEARCH INSTITUTE | 2008-12-25 | — | — | US | disclosed |
| US-7442784-B2 | Ligand activated transcriptional regulator proteins | THE SCRIPPS RESEARCH INSTITUTE (US) | 2008-10-28 | — | — | US | disclosed |
| US-7329728-B1 | Ligand activated transcriptional regulator proteins | THE SCRIPPS RESEARCH INSTITUTE (US) | 2008-02-12 | — | — | US | disclosed |
| US-20030186841-A1 | Ligand activated transcriptional regulator proteins | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-10-02 | — | — | US | disclosed |
| WO-2001030843-A9 | LIGAND ACTIVATED TRANSCRIPTIONAL REGULATOR PROTEINS | NOVARTIS AG (CH) | 2002-09-19 | — | — | WO | disclosed |
| EP-1226168-A1 | LIGAND ACTIVATED TRANSCRIPTIONAL REGULATOR PROTEINS | Novartis AG (CH) | 2002-07-31 | — | — | EP | disclosed |
| WO-2001030843-A1 | LIGAND ACTIVATED TRANSCRIPTIONAL REGULATOR PROTEINS | NOVARTIS AG (CH) | 2001-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222283-A1 | USE OF GAMMA SECRETASE INHIBITORS AND NOTCH PATHWAY INHIBITORS FOR TREATMENT AND PREVENTION OF RENAL DESEASE | BACE1, GSAP, BACE2 | ESR1 3627/4885ESR2 1337/4885MAPT 1834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.